We are translating scientific breakthroughs into therapeutics that can address the symptoms of FSASD and fundamentally alter the course of disease progression
We are establishing powerful new research tools including cell lines, animal models, analytical methods to enable scientists to understand the key drivers behind the disease
We are establishing networks of leading physicians who can conduct clinical studies on patients while supporting studies into the natural history of disease progression
We aim to uncover the many undiagnosed patients living with FSASD while enabling doctors to more rapidly diagnose new cases
STAR is pleased to announce a Request for Proposals (RFP) to support translational research on promising therapies for Free Sialic Acid Storage Disorder (FSASD). A total of $100,000 will be awarded to investigator(s) aiming to evaluate candidate therapeutics in disease relevant pre-clinical models of FSASD.
Applications must be submitted by May 2, 2025 to be considered.
The FSASD Consortium comprises approximately 40 researchers from over 20 leading institutions around the world dedicated to bringing new therapies to patients with free sialic acid disorders. The Consortium meets quarterly to discuss the latest research breakthroughs and how these can be applied to medicine development.
